CHRS Q1 2026: Coherus Oncology’s LOQTORZI Momentum Mixed with Pipeline Ambition

A market-friendly read on CHRS, EPS signals, and the evolving revenue forecast for a specialty immuno-oncology player

Coherus Oncology, Inc. (Nasdaq: CHRS) disclosed a first-quarter 2026 update centered on LOQTORZI (toripalimab-tpzi), with the company highlighting a $11.8 million net revenue figure for Q1 2026. That is a 61% year-over-year rise from Q1 2025 but a 5% step-down versus Q4 2025, a delta the release attributes to weather disruptions and normal seasonality. The press release reads like a product-and-pipeline briefing rather than a traditional earnings summary, and it leaves investors hungry for GAAP earnings per share (EPS) data—no EPS is disclosed in this document, so the EPS consensus and potential earnings surprises will have to wait for the formal filings.

Financial snapshot

Ticker: CHRS; LOQTORZI net revenue in Q1 2026: $11.8 million
YoY growth: +61% vs. Q1 2025
QoQ change: -5% vs. Q4 2025
Cash position: $167.0 million in cash, cash equivalents and marketable securities at quarter-end
Capital markets cue: The release emphasizes revenue milestones and operating momentum rather than a full EPS breakout in this document

Operational and strategic highlights

The release stresses LOQTORZI’s role as the only FDA-approved treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), framing a roughly $250 million addressable market. Management points to robust patient activity: Q1 saw the highest volume of new patient starts to date, driven by both new account starts and deeper engagement with existing ordering accounts, with average treatment duration continuing to grow among current patients.

Beyond LOQTORZI, Coherus is advancing a set of pipelines with an eye toward combo strategies. The IL-27 antagonist Casdozokitug and the CCR8 Treg depleter Tagmokitug are highlighted as differentiators, with claims of dose-responsive immune effects and favorable safety signals, no off-target binding, and broad clinical program expansion. The company also notes continued development of the first-in-class pasritamig combination study in metastatic castration-resistant prostate cancer (mCRPC) and anticipates data readouts in 2026.

Management commentary

“We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI’s potential in NPC and in combination with our pipeline products,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “Casdozokitug is the only known clinical stage IL-27 antagonist, and the first line HCC study in combination with LOQTORZI is now fully enrolled. We are tracking to initial data around mid-year.”

“The tagmokitug program is also on track, with continued enrollment across all cohorts. We also continue to progress the first-in-class pasritamig combination study in metastatic castration-resistant prostate cancer (mCRPC), which we anticipate initiating in the fall. We are on target for multiple data readouts as planned in 2026,”

said Rosh Dias, MD, Chief Medical Officer.

Management also notes cash runway considerations as it courts longer-term value from its immuno-oncology portfolio. A conference call was scheduled for 5:00 p.m. Eastern Daylight Time to discuss the quarter and the business outlook.

Implications for CHRS and its sector peers

The Q1 narrative reinforces a few enduring themes in biotech finance: a single-asset franchise (LOQTORZI) delivering meaningful top-line momentum but requiring ongoing funding for an expanding pipeline. While the reported LOQTORZI revenue provides positive signal, the absence of a disclosed EPS figure or formal EPS consensus for the quarter means the market will be weighing the narrative against GAAP results when they arrive. In the meantime, CHRS’ emphasis on a growing SMS-like addressable market for NPC—coupled with a cash balance that must power both commercialization and clinical exploration—suggests the company is balancing near-term revenue momentum with longer-term pipeline optionality.

From a sector perspective, the IL-27 and CCR8 programs, combined with pasritamig’s potential in prostate cancer, point to a diversified immuno-oncology strategy that could resonate with peers pursuing combination therapies. If Casdozokitug and Tagmokitug begin to show early signals in mid-to-late 2026 data readouts, CHRS could emerge as a case study in how a mid-cap biotech markets a narrow pipeline while pushing a broader, potentially category-defining immunology platform.

Investors should watch for: (1) how EPS figures materialize in the upcoming filings and whether the earnings surprise (or miss) narrative aligns with the revenue trajectory; (2) the trajectory of LOQTORZI’s U.S. uptake versus competing regimens; (3) clarity on the revenue forecast embedded in the company’s mid-year data releases; and (4) the pace and quality of data from the Casdozokitug and Tagmokitug programs and their translational yield into clinical outcomes and potential partnerships.

Bottom line

Coherus’ Q1 2026 update paints a picture of a company with practical revenue momentum around LOQTORZI and a pipeline that reads like a storyboard for a multi-act immuno-oncology play. The absence of immediate EPS detail makes the next filing cycle the first real test of whether the current optimism translates into a durable earnings trajectory or remains a narrative of potential. For CHRS, the central question is whether 2026 can convert pipeline promise into a sustained revenue forecast that satisfies both current holders and new entrants eyeing the NPC franchise and its expanding immuno-oncology constellation.